{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'instructed to alert their healthcare provider as soon as possible if these symptoms arise.', 'Permanent discontinuation of OKZ is required for subjects who develop diverticulitis and/or', 'GI perforation.', 'Any GI perforation or diverticulitis that meets the criteria for seriousness should be reported', 'as an SAE.', '7.4.3.4', 'Hepatotoxicity', 'The Investigator will be asked to provide relevant medical information/documentation (e.g.,', 'laboratory test results) for all serious and non-serious cases of potential hepatotoxicity.', 'Potential hepatotoxicity is defined as laboratory results that fulfill any of the following', 'criteria (in all cases, AST may be substituted for ALT if ALT results are not available):', 'ALT >3x to <5x ULN', 'ALT >5x ULN', 'ALT >3x ULN and total bilirubin >2x ULN', 'Laboratory results that satisfy any of the criteria for potential hepatotoxicity should be', 'followed by a repeat test within 72 hours, which must include total bilirubin, direct and', 'indirect bilirubin, gamma-glutamyl transferase (GGT), INR, alkaline phosphatase, creatine', 'phosphokinase, and hematology assessment. After that, testing should be repeated at least', 'weekly and followed until resolution, stabilization, or return to baseline values. Additional', 'testing may be limited to ALT, AST, alkaline phosphatase, and bilirubin if all other', 'laboratory results are within normal limits. The number of LFTs included in each repeat', 'testing may be further reduced to include only those parameters which remain abnormal (i.e.,', 'abnormalities that stabilize, resolve, or return to within baseline values do not require repeat', 'testing).', 'Potential hepatotoxicity events that fulfill any of the following criteria must also be recorded', 'as SAEs in the eCRF (in all cases, AST may be substituted for ALT if ALT results are not', 'available):', 'ALT >3x ULN and total bilirubin >2x ULN', 'ALT >8x ULN at any time, regardless of total bilirubin or accompanying symptoms', 'ALT >5x ULN for >2 weeks, regardless of total bilirubin or accompanying symptoms.', 'The elevation should be continuous for >2 consecutive weeks. If the level decreases', 'for some time within 2 weeks, subject permanent discontinuation is not mandated, but', 'Amendment 2: 06 March 2019', '106', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'left under Investigator discretion. Resuming the IMP should be discussed on a case by', 'case basis.', 'ALT >3x ULN, accompanied by symptoms which, as determined by the Investigator,', 'are with the result of hepatic injury (e.g., fatigue, nausea, vomiting, right upper', 'quadrant pain or tenderness, fever, rash, eosinophilia [>5%])', 'For SAEs of potential hepatotoxicity, the Investigator should contact the Medical Monitor for', 'guidance, as additional tests are needed to investigate all potential causes of liver toxicity', '(e.g., alcohol use, hepatitis infection, biliary tract disease, and concomitant medications).', 'Work-up includes, but is not limited to:', 'Obtaining a more detailed history of symptoms and prior or concurrent diseases.', 'Obtaining a history of concomitant drug use (including nonprescription medications', 'and herbal/dietary supplement preparations), alcohol use, recreational drug use, and', 'special diets.', 'Ruling out acute viral hepatitis (types A, B, C, D, and E), cytomegalovirus,', 'Epstein-Barr virus, autoimmune or alcoholic hepatitis, nonalcoholic steatohepatitis,', 'hypoxic/ischemic hepatopathy, and biliary tract disease.', 'Obtaining a history of exposure to environmental chemical agents.', 'Obtaining additional tests to evaluate liver function, as appropriate (e.g., INR, direct', 'bilirubin, biliary tract ultrasonography/imaging results, liver biopsy).', 'Considering gastroenterology or hepatology consultations.', 'All additional investigations should be recorded in the eCRF via the EDC system, and all', 'records should be kept as source documents at the study site.', '7.4.3.5', 'Injection Site Reactions', 'An injection site reaction is any untoward medical event occurring at the injection site during', 'or after study treatment administration that can be at least possibly attributed to the study', 'treatment (i.e., the relationship cannot be ruled out).', 'An assessment of pain, redness, swelling, induration, hemorrhage, and itching at the injection', 'site will be performed. At all specified visits (see Table 1), the assessment of injection site', 'reactions that have occurred since the previous visit will be made by the Investigator prior to', 'any administration of study treatment. Injection site reactions noticed after on-site study', 'treatment administration, when the subject is still on site or already at home and recorded', 'Amendment 2: 06 March 2019', '107', 'Confidential']\n\n###\n\n", "completion": "END"}